Portland Global Advisors Cut Its Merck & Co (MRK) Position; 3 Bullish Analysts Covering AGNC Investment Corp. (AGNC)

April 20, 2018 - By Nellie Frank

Merck & Co., Inc. (NYSE:MRK) Logo

Portland Global Advisors Llc decreased Merck & Co (MRK) stake by 31.71% reported in 2017Q4 SEC filing. Portland Global Advisors Llc sold 7,528 shares as Merck & Co (MRK)’s stock declined 4.63%. The Portland Global Advisors Llc holds 16,215 shares with $912,000 value, down from 23,743 last quarter. Merck & Co now has $157.90B valuation. The stock decreased 0.48% or $0.28 during the last trading session, reaching $58.64. About 10.54 million shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since April 20, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Among 12 analysts covering American Capital Agency Corp. (NASDAQ:AGNC), 3 have Buy rating, 2 Sell and 7 Hold. Therefore 25% are positive. American Capital Agency Corp. had 32 analyst reports since July 30, 2015 according to SRatingsIntel. The rating was maintained by Maxim Group with “Buy” on Friday, October 27. The stock of AGNC Investment Corp. (NASDAQ:AGNC) earned “Buy” rating by Compass Point on Thursday, August 13. The firm has “Neutral” rating given on Wednesday, June 29 by Bank of America. RBC Capital Markets maintained it with “Outperform” rating and $24 target in Monday, August 3 report. The stock of AGNC Investment Corp. (NASDAQ:AGNC) earned “Buy” rating by Maxim Group on Friday, February 3. RBC Capital Markets maintained AGNC Investment Corp. (NASDAQ:AGNC) on Wednesday, October 28 with “Outperform” rating. The stock of AGNC Investment Corp. (NASDAQ:AGNC) has “Equal-Weight” rating given on Friday, February 2 by Barclays Capital. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, July 27. Wunderlich upgraded AGNC Investment Corp. (NASDAQ:AGNC) rating on Monday, May 23. Wunderlich has “Buy” rating and $23 target. The rating was downgraded by Morgan Stanley on Wednesday, December 16 to “Underweight”. See AGNC Investment Corp. (NASDAQ:AGNC) latest ratings:

02/02/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $21 New Target: $20 Maintain
01/02/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $19.5 Maintain
01/02/2018 Broker: Maxim Group Rating: Buy New Target: $21.25 Maintain
01/12/2017 Broker: Wells Fargo Rating: Hold New Target: $19.0
27/10/2017 Broker: Maxim Group Rating: Buy New Target: $21.25 Maintain

Analysts await Merck & Co., Inc. (NYSE:MRK) to report earnings on May, 1 before the open. They expect $0.99 EPS, up 12.50% or $0.11 from last year’s $0.88 per share. MRK’s profit will be $2.67 billion for 14.81 P/E if the $0.99 EPS becomes a reality. After $0.98 actual EPS reported by Merck & Co., Inc. for the previous quarter, Wall Street now forecasts 1.02% EPS growth.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 20 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Merck & Co. Inc. had 85 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, October 13 by Bank of America. The stock of Merck & Co., Inc. (NYSE:MRK) has “Buy” rating given on Friday, August 19 by UBS. Jefferies maintained the stock with “Hold” rating in Monday, February 26 report. Morgan Stanley maintained it with “Equal-Weight” rating and $63 target in Wednesday, February 7 report. Leerink Swann maintained it with “Market Perform” rating and $69 target in Monday, October 30 report. Bank of America downgraded the stock to “Neutral” rating in Wednesday, January 27 report. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Piper Jaffray on Thursday, October 26. Jefferies upgraded the stock to “Hold” rating in Tuesday, October 31 report. Cowen & Co maintained the stock with “Market Perform” rating in Wednesday, April 12 report. The rating was initiated by Berenberg on Tuesday, November 24 with “Buy”.

Investors sentiment decreased to 0.94 in 2017 Q4. Its down 0.12, from 1.06 in 2017Q3. It dropped, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. Moreover, Endurant Cap Lp has 1.82% invested in Merck & Co., Inc. (NYSE:MRK). Freestone Capital Ltd Liability Corp owns 0.04% invested in Merck & Co., Inc. (NYSE:MRK) for 9,274 shares. Sandy Spring Financial Bank reported 73,902 shares or 0.38% of all its holdings. First Citizens Savings Bank reported 0.16% stake. Linscomb & Williams reported 0.37% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Connor Clark & Lunn Management Ltd reported 962,311 shares stake. Private Harbour Investment Mngmt Counsel Ltd Company has invested 0.87% in Merck & Co., Inc. (NYSE:MRK). Garland Cap Mgmt invested in 2.75% or 74,350 shares. Endowment Mgmt Limited Partnership owns 63,600 shares for 0.52% of their portfolio. Berson & Corrado Advisors Limited Liability Corp accumulated 8,086 shares. Fiduciary has invested 0.74% in Merck & Co., Inc. (NYSE:MRK). Dixon Hubard Feinour Brown Inc Va holds 24,287 shares or 0.37% of its portfolio. Usca Ria Ltd Liability holds 0.62% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 99,675 shares. American National Registered Advisor invested in 27,330 shares. Ckw Gp invested in 800 shares or 0.01% of the stock.

The stock decreased 0.27% or $0.05 during the last trading session, reaching $18.71. About 2.37M shares traded. AGNC Investment Corp. (NASDAQ:AGNC) has declined 4.38% since April 20, 2017 and is downtrending. It has underperformed by 15.93% the S&P500.

AGNC Investment Corp. operates as a real estate investment trust in the United States. The company has market cap of $7.32 billion. The firm invests in residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by government-sponsored enterprise or by the United States government agency. It has a 9.17 P/E ratio. It funds its investments primarily through short-term borrowings structured as repurchase agreements.

Since February 9, 2018, it had 0 insider buys, and 1 insider sale for $250,290 activity. 13,500 shares were sold by Federico Peter J, worth $250,290 on Friday, February 9.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>